Spire Healthcare Group plc (LON:SPI - Get Free Report)'s stock price traded up 14.1% on Saturday . The stock traded as high as GBX 256.50 ($3.47) and last traded at GBX 247 ($3.34). 9,747,062 shares were traded during trading, an increase of 563% from the average session volume of 1,469,073 shares. The stock had previously closed at GBX 216.50 ($2.93).
Analyst Ratings Changes
Several equities research analysts have recently issued reports on SPI shares. Berenberg Bank reiterated a "buy" rating and set a GBX 280 price target on shares of Spire Healthcare Group in a report on Thursday, July 31st. JPMorgan Chase & Co. reduced their price target on Spire Healthcare Group from GBX 309 to GBX 303 and set an "overweight" rating for the company in a report on Tuesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of GBX 294.33.
Get Our Latest Analysis on SPI
Spire Healthcare Group Trading Down 4.7%
The company has a market capitalization of £947.58 million, a price-to-earnings ratio of 5,119.57, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96. The business has a fifty day moving average price of GBX 218.99 and a 200 day moving average price of GBX 203.96. The company has a debt-to-equity ratio of 62.25, a current ratio of 0.70 and a quick ratio of 0.74.
Spire Healthcare Group (LON:SPI - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported GBX 4.10 EPS for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. On average, equities analysts expect that Spire Healthcare Group plc will post 15.6634747 EPS for the current fiscal year.
About Spire Healthcare Group
(
Get Free Report)
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.
Featured Articles
Before you consider Spire Healthcare Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spire Healthcare Group wasn't on the list.
While Spire Healthcare Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.